The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
Open accessAbstract
Importance: Non-vitamin K oral anticoagulants (NOACs) are commonly prescribed with other medications that share metabolic pathways that may increase major bleeding risk. Objective: To assess the association between use of NOACs with and without concurrent medications and risk of major bleeding in patients with nonvalvular atrial fibrillation. Design, Setting, and Participants: Retrospective cohort study using data from the Taiwan National Health Insurance database and including 91 330 patients with nonvalvular atrial fibrillation who received at least 1 NOAC prescription of dabigatran, rivaroxaban, or apixaban from January 1, 2012, through December 31, 2016, with final follow-up on December 31, 2016. Exposures: NOAC with or without concurrent use of atorvastatin; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconazole, itraconazole, voriconazole, or posaconazole; cyclosporine; erythromycin or clarithromycin; dronedarone; rifampin; or phenytoin. Main Outcomes and Measures: Major bleeding, defined as hospitalization or emergency department visit with a primary diagnosis of intracranial hemorrhage or gastrointestinal, urogenital, or other bleeding. Adjusted incidence rate differences between person-quarters (exposure time for each person during each quarter of the calendar year) of NOAC with or without concurrent medications were estimated using Poisson regression and inverse probability of treatment weighting using the propensity score. Results: Among 91 330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [SD, 10.8]; men, 55.8%; NOAC exposure: dabigatran, 45 347 patients; rivaroxaban, 54 006 patients; and apixaban, 12 886 patients), 4770 major bleeding events occurred during 447 037 person-quarters with NOAC prescriptions. The most common medications co-prescribed with NOACs over all person-quarters were atorvastatin (27.6%), diltiazem (22.7%), digoxin (22.5%), and amiodarone (21.1%). Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin with NOACs had a significant increase in adjusted incidence rates per 1000 person-years of major bleeding than NOACs alone: 38.09 for NOAC use alone vs 52.04 for amiodarone (difference, 13.94 [99% CI, 9.76-18.13]); 102.77 for NOAC use alone vs 241.92 for fluconazole (difference, 138.46 [99% CI, 80.96-195.97]); 65.66 for NOAC use alone vs 103.14 for rifampin (difference, 36.90 [99% CI, 1.59-72.22); and 56.07 for NOAC use alone vs 108.52 for phenytoin (difference, 52.31 [99% CI, 32.18-72.44]; P < .01 for all comparisons). Compared with NOAC use alone, the adjusted incidence rate for major bleeding was significantly lower for concurrent use of atorvastatin, digoxin, and erythromycin or clarithromycin and was not significantly different for concurrent use of verapamil; diltiazem; cyclosporine; ketoconazole, itraconazole, voriconazole, or posaconazole; and dronedarone. Conclusions and Relevance: Among patients taking NOACs for nonvalvular atrial fibrillation, concurrent use of amiodarone, fluconazole, rifampin, and phenytoin compared with the use of NOACs alone, was associated with increased risk of major bleeding. Physicians prescribing NOAC medications should consider the potential risks associated with concomitant use of other drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study
Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y.-H., McAnulty, J. H., Zheng, Z.-J., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005119 · Cited by 4,506
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · Chest · doi:10.1378/chest.10-0134 · Cited by 4,505
The Central Role of the Propensity Score in Observational Studies for Causal Effects
Rosenbaum, P. R., & Rubin, D. B. (1983) · Biometrika · doi:10.2307/2335942 · Cited by 3,261
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.007 · Cited by 1,941
Lunceford, J. K., & Davidian, M. (2004) · Statistics in Medicine · doi:10.1002/sim.1903 · Cited by 1,674
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000471 · Cited by 1,020
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht134 · Cited by 405
Mueck, W., Kubitza, D., & Becka, M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12075 · Cited by 371
LIESENFELD, K. ‐., LEHR, T., DANSIRIKUL, C., REILLY, P. A., CONNOLLY, S. J., EZEKOWITZ, M. D., YUSUF, S., WALLENTIN, L., HAERTTER, S., & STAAB, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04498.x · Cited by 305
McKinney, J. S., & Kostis, W. J. (2012) · Stroke · doi:10.1161/strokeaha.112.655894 · Cited by 294
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw058 · Cited by 269
Jaspers Focks, J., Brouwer, M. A., Wojdyla, D. M., Thomas, L., Lopes, R. D., Washam, J. B., Lanas, F., Xavier, D., Husted, S., Wallentin, L., et al. (2016) · BMJ · doi:10.1136/bmj.i2868 · Cited by 183
Piccini, J. P., Hellkamp, A. S., Washam, J. B., Becker, R. C., Breithardt, G., Berkowitz, S. D., Halperin, J. L., Hankey, G. J., Hacke, W., Mahaffey, K. W., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.018544 · Cited by 177
Li, B.-Z., Threapleton, D. E., Wang, J.-Y., Xu, J.-M., Yuan, J.-Q., Zhang, C., Li, P., Ye, Q.-L., Guo, B., Mao, C., et al. (2015) · BMJ · doi:10.1136/bmj.h4052 · Cited by 176
Chan, Y.-H., Kuo, C.-T., Yeh, Y.-H., Chang, S.-H., Wu, L.-S., Lee, H.-F., Tu, H.-T., & See, L.-C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.062 · Cited by 165
Self-citationOlesen, J. B., Sorensen, R., Hansen, M. L., Lamberts, M., Weeke, P., Mikkelsen, A. P., Kober, L., Gislason, G. H., Torp-Pedersen, C., & Fosbol, E. L. (2015) · Europace · doi:10.1093/europace/euu225 · Cited by 164
Confounding and indication for treatment in evaluation of drug treatment for hypertension
Grobbee, D. E., & Hoes, A. W. (1997) · BMJ · doi:10.1136/bmj.315.7116.1151 · Cited by 129
Ruff, C. T., Giugliano, R. P., & Antman, E. M. (2016) · Circulation · doi:10.1161/circulationaha.116.021831 · Cited by 115
Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
Parasrampuria, D. A., Mendell, J., Shi, M., Matsushima, N., Zahir, H., & Truitt, K. E. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13092 · Cited by 105
Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation
Flaker, G., Lópes, R. D., Hylek, E. M., WOJDYLA, D. M., Thomas, L. E., Al‐Khatib, S. M., Sullivan, R. M., Hohnloser, S. H., Garcia, D. A., Hanna, M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.07.967 · Cited by 100
Coadministration of Dabigatran Etexilate and Atorvastatin
Stangier, J., Rathgen, K., Stähle, H., Reseski, K., Körnicke, T., & Roth, W. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256595 · Cited by 96
Chan, Y., Yen, K., See, L., Chang, S., Wu, L., Lee, H., Tu, H., Yeh, Y., & Kuo, C.-T. (2016) · Stroke · doi:10.1161/strokeaha.115.011476 · Cited by 87
Self-citationAcute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin
Chan, Y., Yeh, Y., See, L., Wang, C., Chang, S., Lee, H., Wu, L., Tu, H., & Kuo, C.-T. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.063 · Cited by 76
Self-citationHigh-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis
Pandit, A. K., Kumar, P., Kumar, A., Chakravarty, K., Misra, S., & Prasad, K. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12540 · Cited by 72
Delavenne, X., Ollier, É., Basset, T., Bertoletti, L., Accassat, S., Garcin, A., Laporte, S., Zufferey, P. J., & Mismetti, P. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12055 · Cited by 71
Stangier, J., Stähle, H., Rathgen, K., Roth, W., Reseski, K., & Körnicke, T. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010393342 · Cited by 58
Wang, Y., Singh, S., & Bajorek, B. V. (2016) · Pharmacy Practice · doi:10.18549/pharmpract.2016.02.706 · Cited by 52
Atar, S., Cannon, C. P., Murphy, S. A., Rosanio, S., Uretsky, B. F., & Birnbaum, Y. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.02.013 · Cited by 44
Lip, G. Y. H., & Nielsen, P. B. (2016) · Circulation · doi:10.1161/circulationaha.115.016713 · Cited by 44
Increased Levels of Rivaroxaban in Patients After Liver Transplantation Treated With Cyclosporine A
Wannhoff, A., Weiss, K. H., Schemmer, P., Stremmel, W., & Gotthardt, D. N. (2014) · Transplantation · doi:10.1097/tp.0000000000000223 · Cited by 43
Romley, J. A., Gong, C. L., Jena, A. B., Goldman, D. P., Williams, B. R., & Peters, A. L. (2015) · BMJ · doi:10.1136/bmj.h6223 · Cited by 40
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin
Wiggins, B. S., Northup, A., Johnson, D., & Senfield, J. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1698 · Cited by 38
Bleeding associated with coadministration of rivaroxaban and clarithromycin
Fralick, M., Juurlink, D. N., & Marras, T. K. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.150580 · Cited by 31
Green, B., Mendes, R. A., der Valk, R. V., & Brennan, P. A. (2016) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12441 · Cited by 15
Cited by
Taiwan’s National Health Insurance Research Database: past and future
Hsieh, C.-Y., Su, C.-C., Shao, S.-C., Sung, S.-F., Lin, S.-J., Yang Kao, Y.-H., & Lai, E. C.-C. (2019) · Clinical Epidemiology · doi:10.2147/clep.s196293 · Cited by 1,213
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Siontis, K. C., Zhang, X., Eckard, A., Bhave, N., Schaubel, D. E., He, K., Tilea, A., Stack, A. G., Balkrishnan, R., Yao, X., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035418 · Cited by 492
Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.053 · Cited by 397
Shao, S., Chan, Y., Kao Yang, Y., Lin, S., Hung, M., Chien, R., Lai, C., & Lai, E. C. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4713 · Cited by 329
Metadata
- Authors
- Chang, S.-H., Chou, I.-J., Yeh, Y.-H., Chiou, M.-J., Wen, M.-S., Kuo, C.-T., See, L.-C., & Kuo, C.-F.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-10-03
- Volume
- 318
- Issue
- 13
- Pages
- 1250
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2764121201
- Cited by
- 394
- References
- 40
- FWCI
- 27.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.